D018841Chemicals & DrugsD12.776.580.216.380780.995198HSP90 Heat-Shock ProteinsFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonAnesthesiologyBiochemistryWake Forest School of MedicineTimothyPardeeTimothy S. Pardee MD, PhD36.08959100000000-80.268599000000001000Pardee, TimothyAssistant ProfessorDavidCaudellDavid L. Caudell DVM, PhD36.08943500000000-80.268632000000001400Caudell, DavidAssociate ProfessorDouglasLylesDouglas S. Lyles PhD36.08919100000000-80.26677800000000233Lyles, DouglasProfessorLowellHartLowell L. Hart MD, FACP36.09103700000000-80.269096000000001965Hart, LowellAssociate Professor26460795Bendell JC, Jones SF, Hart L, Pant S, Moyhuddin A, Lane CM, Earwood C, Murphy P, Patton J, Penley WC, Thompson D, Infante JRCancer investigationBendell JC, Jones SF, Hart L, Pant S, Moyhuddin A, Lane CM, Earwood C, Murphy P, Patton J, Penley WC, Thompson D, Infante JR. A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors. Cancer Invest. 2015; 33(10):477-82.Cancer Invest2015-10-13T00:00:002015A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors.MetinGurcanMetin N. Gurcan PhD36.08862300000000-80.268210999999992189Gurcan, MetinProfessor28679777Canella A, Welker AM, Yoo JY, Xu J, Abas FS, Kesanakurti D, Nagarajan P, Beattie CE, Sulman EP, Liu J, Gumin J, Lang FF, Gurcan MN, Kaur B, Sampath D, Puduvalli VKClinical cancer research : an official journal of the American Association for Cancer ResearchCanella A, Welker AM, Yoo JY, Xu J, Abas FS, Kesanakurti D, Nagarajan P, Beattie CE, Sulman EP, Liu J, Gumin J, Lang FF, Gurcan MN, Kaur B, Sampath D, Puduvalli VK. Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas. Clin Cancer Res. 2017 Oct 15; 23(20):6215-6226.Clin Cancer Res2017-07-05T00:00:002017Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas.20Professor22Associate ProfessorInternal Medicine, General Internal MedicineInternal Medicine, Hematology & OncologyPathology, Comparative Medicine35151844Li T, Mehraein-Ghomi F, Forbes ME, Namjoshi SV, Ballard EA, Song Q, Chou PC, Wang X, Parker Kerrigan BC, Lang FF, Lesser G, Debinski W, Yang X, Zhang WMolecular therapy : the journal of the American Society of Gene TherapyLi T, Mehraein-Ghomi F, Forbes ME, Namjoshi SV, Ballard EA, Song Q, Chou PC, Wang X, Parker Kerrigan BC, Lang FF, Lesser G, Debinski W, Yang X, Zhang W. HSP90-CDC37 functions as a chaperone for the oncogenic FGFR3-TACC3 fusion. Mol Ther. 2022 Apr 06; 30(4):1610-1627.Mol Ther2022-02-10T00:00:002022HSP90-CDC37 functions as a chaperone for the oncogenic FGFR3-TACC3 fusion.true1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Associate ProfessorAssociate Professor17258257Connor JH, McKenzie MO, Parks GD, Lyles DSVirologyConnor JH, McKenzie MO, Parks GD, Lyles DS. Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses. Virology. 2007 May 25; 362(1):109-19.Virology2007-01-26T00:00:002007Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses.22543833Shimp SK, Chafin CB, Regna NL, Hammond SE, Read MA, Caudell DL, Rylander M, Reilly CMCellular & molecular immunologyShimp SK, Chafin CB, Regna NL, Hammond SE, Read MA, Caudell DL, Rylander M, Reilly CM. Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosus. Cell Mol Immunol. 2012 May; 9(3):255-66.Cell Mol Immunol2012-04-30T00:00:002012Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosus.0.3043520.02425227research area of0.6305590.055689111subject area for